Novo Dives On A Key Miss As Its Battle With Lilly Heats Up

Novo Nordisk Stock Stumbles On A Key Miss As Its Battle With Eli Lilly Heats Up

Licensing

Novo Nordisk (NVO) stock plummeted Tuesday on lighter-than-expected June-quarter sales for its new obesity-fighting pill. Analysts are closely watching the developing battle between Novo and Eli Lilly (LLY) which, within the last year, launched pills to help people lose weight. Novo has pulled ahead somewhat after years of trailing Lilly's injections. But during the second quarter, Novo's Wegovy pill generated…

Novo Dives On A Key Miss As Its Battle With Lilly Heats Up

Other newsrooms on this story

Related reading

Weight Loss Drug Titans Slump Below Key Levels. This Is Why.

Lilly climbs, Novo falls as obesity drug battle intensifies

Novo vs. Lilly: Q2's cardiometabolic grudge match

Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in…

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison,…

GLP-1 battle heats up again as Novo claws its way back into race with Lilly